<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04349436</url>
  </required_header>
  <id_info>
    <org_study_id>RPL-003-19</org_study_id>
    <nct_id>NCT04349436</nct_id>
  </id_info>
  <brief_title>A Phase 1B Study of RP1 in Transplant Patients With Advanced Cutaneous Squamous Cell Carcinoma</brief_title>
  <acronym>ARTACUS</acronym>
  <official_title>An Open-Label, Multicenter, Phase 1B Study of RP1 in Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma (CSCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Replimune Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Replimune Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1B study is a multicenter, open-label, study of RP1 to investigate the safety and&#xD;
      tolerability of RP1 for the treatment of advanced CSCC in up to 30 evaluable organ transplant&#xD;
      recipients. This will include patients with either previous renal or hepatic allograft&#xD;
      transplantation and experiencing subsequent documented locally advanced or metastatic CSCC.&#xD;
      The study will enroll a total of 30 evaluable patients. Patients will participate up to&#xD;
      approximately 3 years including a 28-day screening period, up to approximately 1 year&#xD;
      treatment period, and a 2-year follow-up period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RP1 is a genetically modified herpes simplex type 1 virus that is designed to directly&#xD;
      destroy tumors and to generate an anti-tumor immune response. This is a Phase 1B, open label,&#xD;
      multicenter, trial evaluating the safety and tolerability, biodistribution, shedding, and&#xD;
      preliminary efficacy of RP1 in adult hepatic and renal transplant recipients who subsequently&#xD;
      experienced advanced or metastatic CSCC. Patients will be dosed with RP1 by direct or&#xD;
      ultrasound guided intra-tumoral injection into superficial, subcutaneous or nodal tumors. No&#xD;
      transplanted organs will be injected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>RP1 injection</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with treatment-emergent adverse events greater than or equal to Grade 3</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with Serious adverse events (SAEs)</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with Treatment-emergent adverse events</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects experiencing organ allograft rejection</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Duration of response (DOR) of subjects</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with Complete response (CR)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who receive a clinical benefit rate defined as the rate of Complete Response (CR), Progressive Disease (PR), or Stable Disease (SD)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median duration of clinical benefit of subjects</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median disease-free survival of subjects</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year survival rate of subjects</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subject reported quality of life</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes subjects experience in individual tumor sizes, erythema, inflammation and necrosis</measure>
    <time_frame>36 months</time_frame>
    <description>Changes in tumor size will be evaluated using radiologic scans and calipers for externally visible lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the incidence and severity of graft rejection, and the need for increase in immune suppressive therapy,during active treatment and for up to 1 year after last treatment</measure>
    <time_frame>24 months</time_frame>
    <description>Graft rejection will be assessed by clinical presentation and using the standard measures of kidney/liver function (BUN/Creatinine in the former, AST/ALT/bilirubin in the latter) to ensure that there is no evidence of allograft failure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cutaneous Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>RP1, intra-tumoral injection, oncolytic virus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RP1 administered as an intra-tumoral injection every 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RP1, intra-tumoral injection, oncolytic virus</intervention_name>
    <description>Genetically modified herpes simplex type 1 virus</description>
    <arm_group_label>RP1, intra-tumoral injection, oncolytic virus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary agreement to provide written informed consent prior to any study procedures&#xD;
             and the willingness and ability to comply with all aspects of the protocol and&#xD;
             understand the risk to their organ allograft.&#xD;
&#xD;
          2. Patients with histologically or cytologically confirmed recurrent, locally advanced or&#xD;
             metastatic (to skin, soft tissue or lymph nodes) cutaneous squamous cell carcinoma,&#xD;
             who have progressed following local resection or one local (i.e., topical) medical&#xD;
             therapy.&#xD;
&#xD;
          3. Patients who are renal or hepatic organ allograft recipients on a stable&#xD;
             immunosuppressive regimen for at least 12 months prior to study participation with&#xD;
             stable renal and/or hepatic function. NOTE: Patients who require CTLA-4-Ig medications&#xD;
             are excluded.&#xD;
&#xD;
          4. Patients for whom surgical or radiation treatment of lesions is contraindicated.&#xD;
&#xD;
          5. At least 1 lesion that is measurable and injectable by study criteria (tumor of ≥1cm&#xD;
             in longest diameter or ≥1.5 cm in shortest diameter for lymph nodes).&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status ≤1.&#xD;
&#xD;
          7. Anticipated life expectancy &gt; 6 months&#xD;
&#xD;
          8. Baseline ECG without evidence of acute ischemia.&#xD;
&#xD;
          9. All patients must consent to provide archived or newly obtained tumor material (either&#xD;
             formalin-fixed, paraffin-embedded [FFPE] block or 20 unstained slides).&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with an oncolytic therapy or more than one prior CSCC-directed&#xD;
             local/topical therapy.&#xD;
&#xD;
          2. Prior systemic anti-cancer treatment for CSCC.&#xD;
&#xD;
          3. Patients with visceral metastases.&#xD;
&#xD;
          4. Patients with active herpetic infections or prior complications of HSV-1 infection&#xD;
             (e.g. herpetic keratitis or encephalitis).&#xD;
&#xD;
          5. Patients with a history of organ graft rejection within 12 months.&#xD;
&#xD;
          6. Patients with an ANC &lt; 1.0 x 109/L at any point within 3 months of starting therapy.&#xD;
&#xD;
          7. Had systemic infection requiring intravenous (IV) antibiotics or anti-virals, or other&#xD;
             serious infection within 60 days prior to dosing.&#xD;
&#xD;
          8. Patients who require intermittent or chronic use of systemic (oral or intravenous)&#xD;
             anti-virals with known anti-herpetic activity (e.g. acyclovir) unless for organ&#xD;
             allograft preservation.&#xD;
&#xD;
          9. Patients requiring CTLA-4-Ig medications.&#xD;
&#xD;
         10. Ongoing or recent (within 5 years) evidence of significant autoimmune disease that&#xD;
             required treatment with systemic immunosuppressive treatments beyond that required for&#xD;
             maintenance allograft rejection prevention. The following are not exclusionary:&#xD;
             vitiligo, childhood asthma that has resolved, type 1 diabetes, residual hypothyroidism&#xD;
             that requires only hormone replacement, or psoriasis that does not require systemic&#xD;
             treatment.&#xD;
&#xD;
         11. Active infection with hepatitis B virus (HBV), hepatitis C virus (HCV) or human&#xD;
             immunodeficiency virus (HIV).&#xD;
&#xD;
         12. Any history of transplant-related viral infections, such as BK, EBV or CMV, within 3&#xD;
             months of study entry. Patients with a history of hepatitis B or C virus must have&#xD;
             undetectable viral load within 3 months of study entry.&#xD;
&#xD;
         13. Patients with a condition requiring an increase in the patient's usual&#xD;
             immunosuppressive medications within 60 days of study treatment.&#xD;
&#xD;
         14. Known active CNS metastases and/or carcinomatous meningitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Castro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Replimune Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials at Replimune</last_name>
    <phone>1-781-222-9570</phone>
    <email>Clinicaltrials@replimune.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gregory Daniels, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wanxing Chai-Ho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF, Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Katy Tsai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center School of Medicine</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Theresa Medina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jose Lutzky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>773-702-7696</phone>
      <email>uchicagodermtrial@uchospitals.edu</email>
    </contact>
    <investigator>
      <last_name>Diana Bolotin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Meenal Kheterpal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Trisha Wise-Draper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Clarie Verschraegen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jason Luke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Migden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VCU Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew Poklepovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

